Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGN-201 in Bladder Cancer Undergoing Radical Cystectomy
NCT05055050Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TMX-101 in bladder cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Toxicity of concern (TOX) / Safety profile at 1 year. Started Jan 2022; status: active, not recruiting.
02
Drugs
TMX-101
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05055050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055050.